SCHEMBL10352806

SCHEMBL10352806

N#Cc1ccc(Oc2cc(Oc3ccc(C#N)c(C#N)c3)ncn2)cc1C#N

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.51
▸ MAOB P27338 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ MAOA P21397 2/20 0.44
▸ PDE4B Q07343 1/20 0.41
▸ NSD2 O96028 1/20 0.41
▸ NSD3 Q9BZ95 1/20 0.41
▸ AR P10275 4/20 0.38
▸ KMO O15229 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KDR P35968 1/20 0.36
▸ DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10352809 0.94 CYP19A1 (0.54) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL10352210 0.82 ALDH1A1 (0.56) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL29390509 0.80 CYP19A1 (0.65) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL4581525 0.80 CYP19A1 (0.65) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL10353035 0.79 CYP19A1 (0.56) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL1377229 0.78 CYP19A1 (0.62) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL9472016 0.78 CYP19A1 (0.62) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL10352213 0.78 CYP19A1 (0.58) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL18170274 0.77 CYP19A1 (0.61) CYP19A1MAOBALDH1A1HPGDNPSR1
SCHEMBL21610164 0.76 KDR (0.36) CYP19A1MAOBMAOAARSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362239-B2 Heteroaromatic phthalonitriles THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2013-01-29 — — US disclosed
US-8362239-B2 Heteroaromatic phthalonitriles THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2013-01-29 — — US disclosed
US-20120232270-A1 HETEROAROMATIC PHTHALONITRILES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2012-09-13 — — US disclosed
US-20120232270-A1 HETEROAROMATIC PHTHALONITRILES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2012-09-13 — — US disclosed
US-8222403-B2 Heteroaromatic phthalonitriles THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2012-07-17 — — US disclosed
US-8222403-B2 Heteroaromatic phthalonitriles THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2012-07-17 — — US disclosed
US-20110108755-A1 HETEROAROMATIC PHTHALONITRILES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2011-05-12 — — US disclosed
US-20110108755-A1 HETEROAROMATIC PHTHALONITRILES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232270-A1 HETEROAROMATIC PHTHALONITRILES ARNT, PBRM1, NR4A1 CYP19A1 1685/4885MAOB 4053/4885ALDH1A1 1493/4885
US-20110108755-A1 HETEROAROMATIC PHTHALONITRILES ARNT, PBRM1, NR4A1 CYP19A1 1685/4885MAOB 4053/4885ALDH1A1 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback